NASDAQ:MDCX Medicus Pharma (MDCX) Stock Price, News & Analysis $4.41 +0.09 (+2.08%) As of 05/2/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Medicus Pharma Stock (NASDAQ:MDCX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medicus Pharma alerts:Sign Up Key Stats Today's Range$4.12▼$4.7550-Day Range$2.61▼$4.5252-Week Range$1.80▼$6.00Volume45,584 shsAverage Volume51,711 shsMarket Capitalization$59.16 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingStrong Buy Company OverviewMedicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.Read More… Receive MDCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicus Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address MDCX Stock News HeadlinesMedicus Pharma to acquire Antev in strategic biotech dealApril 30, 2025 | uk.investing.comMedicus Pharma (NASDAQ:MDCX) Earns Buy Rating from D. Boral CapitalApril 30, 2025 | americanbankingnews.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 4, 2025 | Porter & Company (Ad)Medicus Pharma signs letter of intent to buy British biotech companyApril 29, 2025 | bizjournals.comMedicus Pharma Ltd (MDCX)April 29, 2025 | investing.comMedicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange TransactionApril 28, 2025 | finance.yahoo.comMedicus Pharma to acquire Antev, expanding pipeline with potentially first-in-class prostate treatmentApril 28, 2025 | proactiveinvestors.comMedicus Pharma to Acquire Antev Ltd. in $75 Million DealApril 28, 2025 | tipranks.comSee More Headlines MDCX Stock Analysis - Frequently Asked Questions How have MDCX shares performed this year? Medicus Pharma's stock was trading at $2.43 on January 1st, 2025. Since then, MDCX shares have increased by 81.5% and is now trading at $4.41. View the best growth stocks for 2025 here. How were Medicus Pharma's earnings last quarter? Medicus Pharma Ltd. (NASDAQ:MDCX) posted its earnings results on Friday, March, 28th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.14. When did Medicus Pharma IPO? Medicus Pharma (MDCX) raised $4 million in an initial public offering on Thursday, November 14th 2024. The company issued 1,000,000 shares at $4.13 per share. Maxim Group LLC acted as the underwriter for the IPO and Brookline Capital Markets was co-manager. Who are Medicus Pharma's major shareholders? Medicus Pharma's top institutional shareholders include Interchange Capital Partners LLC (12.39%). How do I buy shares of Medicus Pharma? Shares of MDCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings3/28/2025Today5/04/2025Next Earnings (Estimated)6/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MDCX Previous SymbolNASDAQ:MDCX CIK1997296 Webwww.medicuspharma.com Phone732-300-3046FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$14.00 Low Stock Price Target$10.00 Potential Upside/Downside+172.1%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares13,415,000Free FloatN/AMarket Cap$59.16 million OptionableN/A BetaN/A Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:MDCX) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.